Software & SaaS

New Phase 2 data shows Elicio's off-the-shelf therapy ELI-002 7P induces "antigen spreading," creating a personalized anti-tumor response.

Astellas Pharma's new deal with venture studio Autobahn Labs isn't just a partnership; it's a strategic overhaul of the R&D pipeline. Here's why.

Beyond a simple acquisition, ZenaTech is executing a bold strategy to digitize the American West, transforming old-guard industries with a DaaS network.

The latest O-RAN PlugFest showcases major AI integration and a shift to live networks, but the path to widespread commercial adoption remains complex.

A tech-driven 'anti-CRO' and a clinical accelerator have joined forces. Can their integrated model finally fix the broken drug development pipeline?

Senzing's acquisition of Placekey is more than a merger; it’s a bid to create a universal data language. But can an open standard thrive under corporate rule?

A Delaware Supreme Court ruling revives a massive liability risk for Loews, extending a seven-year legal battle over its 2018 Boardwalk Pipelines deal.

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

Biomerica's regulatory win in Egypt is more than a market entry; it's a strategic move to disrupt healthcare with low-cost, rapid diagnostic tools.

The fintech firm launched multicurrency accounts that unify traditional money and stablecoins, aiming to disrupt global payments for businesses.

byNordic Acquisition Corp. buys another month in its search for a Nordic tech merger, but each extension drains funds and tests investor patience.

Brink's new $750M share repurchase is more than a financial move; it’s a bold declaration that its digital transformation is generating serious cash.

Beyond the ad break: How TripleLift's focus on creative formats, global retail media partnerships, and AI is disrupting the programmatic advertising landscape.

A third-generation family takeover, backed by Canada's BDC, positions a 70-year-old firm to accelerate innovation in the competitive medical imaging market.

A new 24g wearable device promises clinic-grade laser therapy for just $99. Can its high-power science truly democratize healing, or is it just hype?

Praxis Precision Medicines secures a clear path to market for its rare epilepsy drug, blending genetic science with a savvy regulatory strategy.

Abeona Therapeutics' new treatment center for ZEVASKYN marks a strategic leap in gene therapy access, but what does it mean for patients and the market?

With a new $6.5M investment, Double is tackling the accounting talent crisis with AI that empowers professionals, not replaces them. Here's why.

As esports races toward a $7.5B market, specialized hardware is king. Inside ZOWIE's strategy to win the high-stakes game of competitive tech.

Nasdaq-listed Caliber moves beyond passive holding, staking 75,000 LINK to actively generate yield. A look at the high-stakes strategy bridging Wall Street and Web3.